Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gravis G, Billon E, Baldini C, Massard C, Hilgers W, Delva R, Walz J, Pignot G, Rybikowski S, Dermeche S, Thomassin J, Brunelle S, Lavaud P, Loriot Y; French Genito-Urinary Tumor Group (GETUG). Gravis G, et al. Among authors: massard c. Eur J Cancer. 2018 Nov;104:236-238. doi: 10.1016/j.ejca.2018.09.002. Epub 2018 Oct 11. Eur J Cancer. 2018. PMID: 30316610 No abstract available.
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. Among authors: massard c. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.
New agents in metastatic prostate cancer.
Fizazi K, Massard C. Fizazi K, et al. Among authors: massard c. Eur J Cancer. 2009 Sep;45 Suppl 1:379-80. doi: 10.1016/S0959-8049(09)70056-5. Eur J Cancer. 2009. PMID: 19775638 No abstract available.
Minimal residual disease in solid neoplasia: New frontier or red-herring?
Mordant P, Loriot Y, Lahon B, Castier Y, Lesèche G, Soria JC, Massard C, Deutsch E. Mordant P, et al. Among authors: massard c. Cancer Treat Rev. 2012 Apr;38(2):101-10. doi: 10.1016/j.ctrv.2011.04.014. Epub 2011 May 25. Cancer Treat Rev. 2012. PMID: 21612875 Review.
Tumour growth rates and RECIST criteria in early drug development.
Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC. Gomez-Roca C, et al. Among authors: massard c. Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15. Eur J Cancer. 2011. PMID: 21763126
465 results